Humor & Quirks
ST. PAUL, Minn.--([ BUSINESS WIRE ])--Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device company developing and commercializing innovative, interventional treatment systems for vascular disease, will present at the Stifel Nicolaus 2012 Healthcare Conference at The Four Seasons Hotel in Boston at 2:05 p.m. ET on Wednesday, September 5, 2012. President and Chief Executive Officer David L. Martin and Chief Financial Officer Laurence L. Betterley will provide an overview of the company and its initiatives.
WHEN: | Stifel Nicolaus 2012 Healthcare Conference | ||
| Wednesday, September 5; 2:05 p.m. ET | |||
| The Four Seasons | |||
| Boston | |||
WEBCAST: | To listen to a live webcast of the presentation, go to the investor information section of the companyas website, [ www.csi360.com ], and click on the webcast icon. | ||
If you have any difficulty accessing the webcast, please contact Mick Forgey: (612) 455-1789; [ mforgey@padillaspeer.com ] | |||
|
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The companyas Diamondback 360, and next generation electric-drive Stealth 360, Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback 360 in August 2007 and Stealth 360 in March 2011. The Stealth 360 has been rapidly adopted and is expected to accelerate the growth of orbital atherectomy in the future. To date, more than 70,000 PAD procedures have been performed using CSIas technology in leading institutions across the United States. CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States.
For more information, visit the companyas website at [ www.csi360.com ].